Axsome Therapeutics Announces AXS-07 Achieves Co-Primary and Key Secondary Endpoints in MOMENTUM Phase 3 Migraine Trial in Patients with History of Inadequate Response
December 30, 2019 06:15 ET
|
Axsome Therapeutics, Inc.
Demonstrated statistical significance on regulatory co-primary endpoints of pain freedom (p<0.001) and freedom from most bothersome symptom (p=0.002) at 2 hours, compared to placebo Demonstrated...
IntelGenx and Aquestive Therapeutics Enter Worldwide Collaboration Agreement for Tadalafil
May 08, 2019 07:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 08, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has entered into a...
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
May 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator ...
IntelGenx Granted Japanese Patent for RIZAPORT® VersaFilm™
February 11, 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Feb. 11, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that it has received a Decision...
IntelGenx Strengthens Senior Management Team
February 07, 2019 16:00 ET
|
IntelGenx Technologies Corp.
SAINT-LAURENT, Québec, Feb. 07, 2019 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT), today announced that it has strengthened its management team with the...
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
February 06, 2019 07:00 ET
|
Axsome Therapeutics, Inc.
FDA agreement achieved on Phase 3 trial design, endpoints, and statistical approach Trial to enroll patients with a history of inadequate response to prior migraine treatments Trial initiation...
IntelGenx Partners with Gensco® Pharma to Market RIZAPORT® in the United States
December 12, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 12, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive...
IntelGenx Reports Third Quarter 2018 Financial Results
November 08, 2018 16:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Nov. 08, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today reported financial results for the third quarter...
IntelGenx Announces Successful Results from RIZAPORT® Bioequivalence Study
September 24, 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Sept. 24, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced successful results from a bioequivalence study for...
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
February 13, 2015 10:18 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel, Feb. 13, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...